Genocea Biosciences Inc. buy mixitrader
Summary
This prediction ended on 08.01.22 with a price of €0.94. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.85%. mixitrader has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Genocea Biosciences Inc. | - | - | - |
iShares Core DAX® | -1.471% | 1.895% | 25.178% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% |
Comments by mixitrader for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.